AlphaRx reports positive preclinical results of GAI-122 injectable nanoemulsion for Acute Ischemic Stroke

Download PDF Copy

Jul 13 2010

AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results of GAI-122 injectable nanoemulsion, a Mitochondria-targeted neuroprotective drug candidate being developed for the treatment of Acute Ischemic Stroke. The results will be delivered as a podium presentation during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon July 10 - 14, 2010.

On Wednesday, July 14, 2010, Dr. Joseph Schwarz, Chief Scientist of AlphaRx, will make an oral podium presentation of GAI-122 injectable nanoemulsion for neuroprotection. The results conclude that, based on the neuroprotective properties of GAI-122 and the increased concentration of GAI-122 in the brain after parenteral delivery relative to oral dosing, it is reasonable to expect that an injectable form of GAI-122 based on a nanoemulsion, will provide the required protection against damage to cognitive and behavioral functions in humans experiencing various ischemic disorders.

Source:

AlphaRx Inc.

Posted in: Drug Trial News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

NYU Langone stroke team delivers lifesaving care with record speed

Can the gut microbiome adapt to protect the brain after stroke?

Living in food deserts linked to higher stroke and death risk in atrial fibrillation patients

FAST walk shows promise in improving gait for chronic stroke patients

Newly discovered biological pathway explains clotting risk in people with type 2 diabetes

Study identifies why stroke impairs ability to use word meanings in reading

Native Hawaiian and Pacific Islander people face highest stroke rates in the U.S.

Postmenopausal women with stroke history can safely use vaginal estrogen

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.